Introduction {#section1-1534735417734913}
============

Liver cancer is a major cause of cancer-related mortality worldwide. In 2013, primary liver cancer, as reported by the World Health Organization, caused 745 517 deaths over the world, and hepatocellular carcinoma (HCC) represented the majority of these liver cancers.^[@bibr1-1534735417734913]^ In China, HCC ranks the second most common cause of cancer-related mortality with an annual mortality rate of 24.15 per 100 000 persons in 2009.^[@bibr2-1534735417734913]^ Moreover, approximately 383 203 persons die from liver cancer annually in China, which accounts for 51% of the deaths from liver cancer worldwide.^[@bibr2-1534735417734913]^

The Barcelona Clinic Liver Cancer (BCLC) classification system is widely adopted as the treatment algorithm for HCC, which has been endorsed by the European Association for the Study of the Liver (EASL) and the American Association for the Study of the Liver Disease (AASLD).^[@bibr3-1534735417734913][@bibr4-1534735417734913]-[@bibr5-1534735417734913]^ It provides guidance on both the recommended therapy and corresponding prognosis at the presenting stages. Most HCCs are diagnosed at an intermediate to advanced stage with few effective therapeutic options available.^[@bibr6-1534735417734913]^ Transarterial chemoembolization (TACE) is recommended as the first-line therapy for patients with intermediate stage HCC in BCLC stage classification (single nodule \>5 cm or multinodular tumors \>3 cm; Okuda stage I-II; Child-Pugh A-B; Eastern Cooperative Oncology Group (ECOG) performance status test 0).^[@bibr4-1534735417734913],[@bibr5-1534735417734913],[@bibr7-1534735417734913],[@bibr8-1534735417734913]^ However, the prognosis of patients with intermediate stage HCC remains poor, with a reported median survival of 19 to 34 months, and 3-year survival rate of 29% to 47%, respectively.^[@bibr9-1534735417734913][@bibr10-1534735417734913]-[@bibr11-1534735417734913]^ Therefore, search for a more effective therapy for this cohort of patients is still imperative.

Recently, traditional Chinese medicines (TCMs, including plants, animal parts, and minerals) have aroused a great deal of interest for their potential therapeutic effects on HCC. Previous studies demonstrated that TCMs were able to retard HCC progression through multiple actions, such as tumor growth inhibition, anti-metastatic, anti-inflammation, anti--liver cancer stem cells activities and other activities.^[@bibr12-1534735417734913]^ Kang'ai (KA) injection is a composite anti-tumor formula for injection that mainly consists of five active molecules, namely ginsenosides Rg1, Re, Rf, Rb1, and astragaloside at concentrations of 118.33 µg/mL, 75.06 µg/mL, 12.56 µg/mL, 34.06 µg/mL, and 56.50 µg/mL, respectively.^[@bibr13-1534735417734913]^ The formula was reported to be able to improve immune function and raise white blood cell (WBC) count; inhibit tumor cell cloning; arrest cell cycle, induce apoptosis, and suppress invasion and metastasis of cancer cells from lung cancer, intestinal carcinoma and HCC.^[@bibr14-1534735417734913]^ To the best of our knowledge, there is no study that has investigated the effect of TACE in combination with KA injection on patients with intermediate stage HCC in the literature.

So, we conducted this study to evaluate the efficacy and safety of combining KA injection with TACE for treating patients with HCC at intermediate stage.

Patients and Methods {#section2-1534735417734913}
====================

Patients and Study Design {#section3-1534735417734913}
-------------------------

Between November 2013 and March 2017, a total of 134 consecutive HCC patients were diagnosed and treated in our unit. Inclusion criteria were as follows: (1) ages between 18 and 75 years, (2) intermediate HCC in BCLC stage classification,^[@bibr4-1534735417734913],[@bibr5-1534735417734913],[@bibr7-1534735417734913],[@bibr8-1534735417734913]^ and (3) TACE with or without KA therapy. Exclusion criteria included (1) human immunodeficiency (HIV) infection or active tuberculosis; (2) extrahepatic malignancy; (3) chronic cardiovascular, respiratory, or renal diseases; (4) previous history of organ transplantation; (5) pregnant or breastfeeding women; (6) contraindications to an arterial procedure such as impaired clotting tests (platelet count \<50 × 10^9^/L or prothrombin activity \<50%); (7) using other herbal remedies outside of medical treatment. As shown in [Figure 1](#fig1-1534735417734913){ref-type="fig"}, we excluded 45 patients: 14 with early HCC in BCLC stage classification and good hepatic function who were transferred to receive hepatic resection, 9 undergoing multimodality therapy (including TACE followed by radiofrequency ablation or hepatic resection), 8 denying any invasive therapy (either hepatic resection, TACE or radiofrequency ablation), 6 with major vascular invasion and/or distant metastasis, 5 receiving other herbal remedies outside of medical treatment and 3 lost to follow-up. The remaining 89 patients with intermediate stage HCC were enrolled in this study and divided into concurrent group receiving both repeated TACE plus KA injection (n = 48) and monotherapy group receiving only repeated TACE (n = 41). KA injection was only applied to patients who consented to use it after providing detailed information regarding the safety, efficacy, and cost to patients and their family members, and after discussion with their physicians. All study procedures were in accordance with the ethical standards of the ethics committee of the Second Affiliated Hospital of Kunming Medical University on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008, and signed informed consents were obtained from all patients.

![Disposition of patients in this study.](10.1177_1534735417734913-fig1){#fig1-1534735417734913}

Diagnostic Criteria {#section4-1534735417734913}
-------------------

All HCC diagnoses were made according to the diagnostic criteria recommended by the EASL and the AASLD guidelines on noninvasive diagnosis.^[@bibr4-1534735417734913],[@bibr15-1534735417734913]^ Radiologic imaging techniques, including ultrasound (US), triphasic computed tomography (CT), and contrast-enhanced magnetic resonance imaging (MRI), were applied to characterize the tumors. In principle, a unique dynamic radiological behavior (contrast uptake in the arterial phase by CT, MRI, angiography, or US) represented the radiologic hallmark of HCC. When showing the radiological hallmark of HCC, noninvasive diagnosis can be established by one imaging technique in nodules above 2 cm and 2 coincidental techniques (CT, MRI, and US contrast) in nodules of 1 to 2 cm in diameter.

TACE Procedure {#section5-1534735417734913}
--------------

TACE was performed in a sterile operating room by two highly experienced interventional radiologists in our institution according to the method described by Chung et al.^[@bibr16-1534735417734913]^ Briefly, after local anesthesia, the right superficial femoral artery was punctured with Seldinger technique. A 5-F French catheter was introduced into the abdominal aorta under fluoroscopy guidance. Selective angiography via the superior mesenteric artery or the common hepatic artery was performed to identify the exact site of HCC and its feeding arteries. After catheterization, a 2.7-F French catheter was advanced through the 5-F catheter into the feeding arteries. An emulsion of 10 to 15 mL lipiodol (Andre Guerbet, Aulnay-sous-Bois, France) and 3 anticancer agents (ie, 100-150 mg oxaliplatin, 500-750 mg 5-fluorouracil and 10-20 mg epirubicin) followed by 1- to 2-mm diameter gelatin sponge particles (Cutanplast; MasciaBrunelli, Milan, Italy) was slowly injected into the feeding arteries. The dose of emulsion of lipiodol and anticancer agents, and the pieces of embolic materials used for TACE were determined by the tumor size and extent of the lesions.

Follow-up and Treatment Protocol {#section6-1534735417734913}
--------------------------------

After TACE, patients were prospectively followed up every 1 to 3 months during the first year and at 3- to 6-month intervals thereafter in our unit till death or till the censor time of the study (March 2017). At each visit, medical interviews (concerning adherence to antiviral therapy, treatment-related adverse events, and cirrhosis complications), physical examination, laboratory tests (liver and kidney functions, coagulation, lipids, glucose and electrolytes profiles, α-fetoprotein \[AFP\], and hepatitis B virus (HBV)-DNA, etc), radiologic imaging tests (abdominal US, chest X-ray, dynamic abdominal CT, or MRI) were performed in all patients. Chest CT or bone scans were performed when distant metastasis was suspected. Data were documented in our electronic medical record system. All tumor responses were independently evaluated by 2 expert radiologists (Profs Zhu and Pu, both with more than 20 years of experience) who were blinded to our study protocol. And all tumors were evaluated for response using dynamic radiologic modalities (CT or MRI) according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST).^[@bibr17-1534735417734913]^ For patients who showed viable tumor lesions (contrast uptake in arterial phase) or intrahepatic metastasis or new lesions, if clinically feasible, repeated TACE was performed by respective physicians, who made the decisions based on extrahepatic disease, hepatic function, general health, patient willingness, and economic conditions. For patients in concurrent group, KA injection (Changbai Mountain Pharmaceutical co, Ltd) was intravenously given at a standard dose of 40 mL (ie, ginsenosides Rg1 4.73 mg, Re 3.00 mg, Rf 0.50 mg, Rb1 1.36 mg, and astragaloside 2.26 mg) in 250 mL normal saline per day for a median of 15 days (range 11-20 days) during in-hospital time at each episode of TACE. Vigorous oral nucleos(t)ides including tenofuvir, entecavir, and lamivudine were administered to patients with detectable HBV-DNA. Ascitic patients received oral diuretics and/or albumin infusion. All patients received hepatic cytoprotective and regenerative agents (ie, glycyrrhizin, reduced glutathione, polyene phosphatidylcholine, and ademetionine).

Endpoints {#section7-1534735417734913}
---------

Primary endpoints were overall survival (OS) and time to radiologic progression (TTP). OS was defined as the time period from the initial TACE to the date of death of any cause. TTP was calculated as the time between the initial TACE and the objective tumor progression, which was evaluated according to the mRECIST criteria.^[@bibr17-1534735417734913]^ Objective tumor progression referred to ≥20% increment in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started or intrahepatic metastasis or macrovascular invasion or extrahepatic metastasis.^[@bibr17-1534735417734913]^

Statistical Analysis {#section8-1534735417734913}
--------------------

Continuous variables were expressed as mean ± standard deviation (SD) or median and ranges, and compared using Student's *t* test or the Mann-Whitney *U* test, as appropriate. Categorical variables were presented as the number of events and percentage, and compared by the χ^2^ test. Survival analyses were performed using the Kaplan-Meier method and compared by the log-rank test. Baseline factors associated with survival were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. Multivariate analysis was conducted using variables that showed association in univariate analysis with a *P* value \<.1. All statistical analyses were executed with SPSS 17.0 software (SPSS Inc, Chicago, IL).

Results {#section9-1534735417734913}
=======

Patient Characteristics {#section10-1534735417734913}
-----------------------

As shown in [Table 1](#table1-1534735417734913){ref-type="table"}, the baseline characteristics of patients in the 2 groups were statistically comparable (*P* \> .05). Male patients were predominant in both groups, accounting for 87.5% and 78.0% in the TACE + KA and TACE groups, respectively. The majority of patients in both groups were with Child-Pugh class B, HBV infection, maximum tumor size between 5.0 and 10.0 cm, 2 to 3 tumors, AFP levels \<200 ng/mL, and no ascites. The 2 groups had similar ages and serum levels of albumin, alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), creatinine, prothrombin time (PT), white blood cell (WBC), hemoglobin (HGB), platelet count (PLT), and HBV-DNA. The average follow-up periods were 18.7 and 16.3 months in the TACE + KA and TACE groups, respectively.

###### 

Baseline Demographic and Disease Characteristics of Patients in TACE + KA and TACE Groups.

![](10.1177_1534735417734913-table1)

  Background Factors                                       TACE + KA Group (n = 48)          TACE Group (n = 41)              *P*
  -------------------------------------------------------- --------------------------------- -------------------------------- ------
  Age, y, mean ± SD                                        53.9 ± 10.3                       55.7 ± 8.8                       .385
  Male, n (%)                                              42 (87.5)                         32 (78.0)                        .235
  Child-Pugh class, n (%)                                                                                                     
   A                                                       22 (45.8)                         20 (48.8)                        .781
   B                                                       26 (54.2)                         21 (51.2)                        
  Etiology, n (%)                                                                                                             
   HBV                                                     33 (68.8)                         32 (78.0)                        .728
   HCV                                                     7 (14.6)                          5 (12.2)                         
   Alcohol                                                 3 (6.3)                           1 (2.4)                          
   Other                                                   5 (10.4)                          3 (7.3)                          
  Maximum tumor size (cm), n (%)                                                                                              
   3.1-5.0                                                 17 (35.4)                         7 (17.1)                         .151
   5.1-10.0                                                21 (43.8)                         23 (56.1)                        
   ≥10.1                                                   10 (20.8)                         11 (26.8)                        
  No. of lesions, n (%)                                                                                                       
   1                                                       12 (25.0)                         18 (43.9)                        .115
   2-3                                                     32 (66.7)                         22 (53.7)                        
   ≥4                                                      4 (8.3)                           1 (2.4)                          
  α-Fetoprotein (0-10 ng/mL), n (%)                                                                                           
   \<200 ng/mL                                             34 (70.8)                         22 (53.7)                        .247
   200-1000 ng/mL                                          6 (12.5)                          8 (19.5)                         
   \>1000 ng/mL                                            8 (16.7)                          11 (26.8)                        
  Albumin (35-50 g/L), mean ± SD                           34.4 ± 6.2                        32.5 ± 4.5                       .113
  ALT (5-40 U/L), mean ± SD                                53.0 ± 32.2                       51.0 ± 33.2                      .769
  AST (8-40 U/L), mean ± SD                                75.4 ± 40.4                       78.1 ± 37.2                      .746
  Total bilirubin (3.4-17.1 µmol/L), mean ± SD             20.4 ± 7.5                        22.7 ± 9.6                       .200
  Direct bilirubin (0-5.1 µmol/L), mean ± SD               9.0 ± 4.0                         10.6 ± 5.9                       .114
  Creatine (62-115 µmol/L), mean ± SD                      72.7 ± 15.6                       73.1 ± 22.7                      .912
  Prothrombin time (11.0-15.0 s), mean ± SD                15.0 ± 2.2                        15.7 ± 2.2                       .192
  White blood cell count (3.50-9.50 ×10^9^/L), mean ± SD   5.14 ± 2.08                       4.52 ± 1.71                      .132
  Hemoglobin (130-175 g/L), mean ± SD                      125.5 ± 29.4                      122.3 ± 27.6                     .602
  Platelet count (125-350 ×10^9^/L), mean ± SD             119.3 ± 60.1                      135.1 ± 81.7                     .299
  HBV-DNA (log~10~ copies/mL), mean ± SD                   3.96 ± 1.46 (n = 33)              4.09 ± 1.43 (n = 32)             .732
  Ascites, no/mild/moderate to severe, n (%)               27 (56.3%)/12 (25.0%)/9 (18.8%)   24 (58.5%)/14 (34.1%)/3 (7.3%)   .247
  No. of TACE sessions, mean ± SD                          3.1 ± 1.6                         3.0 ± 1.5                        .723
  Follow-up period (mo), mean ± SD                         18.7 ± 8.3                        16.3 ± 8.1                       .180

Abbreviations: TACE, transarterial chemoembolization; KA, Kang'ai injection; HBV, hepatitis B virus; HCV, hepatitis C virus; ALT, alanine transaminase; AST, aspartate transaminase.

Clinical Efficacy {#section11-1534735417734913}
-----------------

As shown in [Figure 2](#fig2-1534735417734913){ref-type="fig"}, the TACE + KA group had a median OS period of 27.0 months (95% confidence interval \[CI\] 21.7-32.3), compared with 21.0 months (95% CI 15.6-26.4) in the TACE group (hazard ratio \[HR\] 0.658, 95% CI 0.377-0.982; *P* = .038). The 1-, 2-, and 3-year OS rates were 88.5%, 58.8%, and 20.8% in the TACE + KA group, compared with 81.3%, 44.9%, and 6.7% in the TACE group (*P* = .038).

![Cumulative overall survival rates of patients in TACE + KA and TACE groups (*P* = .038 by log-rank test). TACE, transarterial chemoembolization; KA, Kang'ai injection.](10.1177_1534735417734913-fig2){#fig2-1534735417734913}

In [Figure 3](#fig3-1534735417734913){ref-type="fig"}, the TACE+KA group showed a significantly longer median TTP period (12.0 months, 95% CI 12.0-14.0) than the TACE group (10.0 months, 95% CI 8.2-11.8) (HR 0.694, 95% CI 0.411-0.965; *P* = .028). The 1- and 2-year TTP rates were, respectively, 49.3% and 86.9% in the TACE + KA group, compared with 75.3% and 100% in the TACE group (*P* = .028). We performed a further analysis on tumor progression ([Table 2](#table2-1534735417734913){ref-type="table"}), which revealed that patients receiving TACE + KA had significantly lower frequencies of intrahepatic and extrahepatic metastases than those receiving TACE alone (*P* \< .05), while frequencies of increased viable tumor tissue of TACE-targeted lesions and major vascular invasion were comparable (*P* \> .05).

![Cumulative TTP rates of patients in TACE + KA and TACE groups (*P* = .028 by log-rank test). TTP, time to radiologic progression; TACE, transarterial chemoembolization; KA, Kang'ai injection.](10.1177_1534735417734913-fig3){#fig3-1534735417734913}

###### 

Tumoral Progression of Patients in the TACE + KA and TACE Groups.

![](10.1177_1534735417734913-table2)

  Group                                                         Increased viable Tumoral Tissue   Intrahepatic Metastasis   Major Vascular Invasion   Extrahepatic Metastasis
  ------------------------------------------------------------- --------------------------------- ------------------------- ------------------------- -------------------------
  TACE + KA, n (%)                                              8 (16.7)                          22 (45.8)                 21 (43.8)                 12 (25.0)
  TACE, n (%)                                                   9 (22.0)                          28 (68.3)                 24 (58.5)                 19 (46.3)
  *P* ^[a](#table-fn3-1534735417734913){ref-type="table-fn"}^   .527                              .033                      .164                      .035

Abbreviations: TACE, transarterial chemoembolization; KA, Kang'ai injection.

*P* value for comparison between TACE + KA and TACE groups.

Baseline Factors Affecting the OS and TTP of Patients {#section12-1534735417734913}
-----------------------------------------------------

Baseline laboratory variables were taken as the date when the initial session of TACE was performed. Univariate analysis revealed that the following 7 factors were independent prognostic variables for OS: group (HR 0.524, 95% CI 0.282-0.975, *P* = .031), maximum tumor size (HR 1.156, 95% CI 1.046-1.277, *P* = .004), tumor number (HR 0.632, 95% CI 0.401-0.998, *P* = .029), albumin (HR 0.937, 95% CI 0.883-0.995, *P* = .033), AST (HR 1.007, 95% CI 1.001-1.014, *P* = .029), TBIL (HR 1.048, 95% CI 1.008-1.089, *P* = .018), and DBIL (HR 1.101, 95% CI 1.040-1.166, *P* = .031) ([Table 3](#table3-1534735417734913){ref-type="table"}). However, multivariate analysis showed that only the following 3 factors remained as independent prognostic variables: group (HR 0.658, 95% CI 0.377-0.982, *P* = .023), maximum tumor size (HR 1.152, 95% CI 1.020-1.302, *P* = .019), and tumor number (HR 0.629, 95% CI 0.386-0.987, *P* = .034) ([Table 3](#table3-1534735417734913){ref-type="table"}).

###### 

Univariate and Multivariate Cox Analysis of Prognostic Factors for Overall Survival.

![](10.1177_1534735417734913-table3)

  Baseline Variables                                                          Univariate Analysis   Multivariate Analysis                                
  --------------------------------------------------------------------------- --------------------- ----------------------- ------ ------- ------------- ------
  Group^[a](#table-fn5-1534735417734913){ref-type="table-fn"}^                0.524                 0.282-0.975             .031   0.658   0.377-0.982   .023
  Maximum tumor size^[b](#table-fn6-1534735417734913){ref-type="table-fn"}^   1.156                 1.046-1.277             .004   1.152   1.020-1.302   .019
  Tumor number^[c](#table-fn7-1534735417734913){ref-type="table-fn"}^         0.632                 0.401-0.998             .029   0.629   0.386-0.987   .034
  Albumin                                                                     0.937                 0.883-0.995             .033                         
  AST                                                                         1.007                 1.001-1.014             .029                         
  TBIL                                                                        1.048                 1.008-1.089             .018                         
  DBIL                                                                        1.101                 1.040-1.166             .031                         

Abbreviations: HR, hazard ratio; CI, confidence interval; AST, aspartate transaminase; TBIL, total bilirubin; DBIL, direct bilirubin; AFP, α-fetorpotein; TACE, transarterial chemoembolization; KA, Kang'ai injection.

Group: TACE + KA = 2, TACE = 1.

Maximum tumor size: 3.1-5.0 cm=1, 5.1-10.0 cm = 2, ≥10.1 cm = 3.

Tumor number: 1 tumor = 1, 2-3 tumors = 2, ≥4 tumors = 3.

As for TTP, univariate analysis demonstrated the following 5 factors as independent prognostic variables: group (HR 0.646, 95% CI 0.407-0.946, *P* = .027), maximum tumor size (HR 1.176, 95% CI 1.102-1.255, *P* \< .001), tumor number (HR 0.576, 95% CI 0.416-0.796, *P* = .001), DBIL (HR 1.060, 95% CI 1.010-1.112, *P* = .038), and AFP level (HR 1.894, 95% CI 1.390-2.580, *P* \< .001) ([Table 4](#table4-1534735417734913){ref-type="table"}). The multivariate analysis showed only the following 3 factors as independent prognostic factors: group (HR 0.694, 95% CI 0.411-0.965, *P* = .046), maximum tumor size (HR 1.139, 95% CI 1.049-1.237, *P* = .002), and AFP level (HR 1.481, 95% CI 1.064-2.060, *P* = .020) ([Table 4](#table4-1534735417734913){ref-type="table"}).

###### 

Univariate and Multivariate Cox Analysis of Prognostic Factors for Time to Radiologic Progression.

![](10.1177_1534735417734913-table4)

                                                                               Univariate Analysis   Multivariate Analysis                                
  ---------------------------------------------------------------------------- --------------------- ----------------------- ------ ------- ------------- ------
  Group^[a](#table-fn9-1534735417734913){ref-type="table-fn"}^                 0.648                 0.407-0.946             .027   0.694   0.411-0.965   .046
  Maximum tumor size^[b](#table-fn10-1534735417734913){ref-type="table-fn"}^   1.176                 1.102-1.255             .000   1.139   1.049-1.237   .002
  AFP^[c](#table-fn11-1534735417734913){ref-type="table-fn"}^                  1.894                 1.390-2.580             .000   1.481   1.064-2.060   .020
  Tumor number^[d](#table-fn12-1534735417734913){ref-type="table-fn"}^         0.576                 0.416-0.796             .001                         
  DBIL                                                                         1.060                 1.010-1.112             .038                         

Abbreviations: HR, hazard ratio; CI, confidence interval; AFP, α-fetoprotein; DBIL, direct bilirubin; TACE, transarterial chemoembolization; KA, Kang'ai injection.

Group: TACE + KA = 2, TACE = 1.

Maximum tumor size: 3.1-5.0 cm = 1, 5.1-10.0 cm = 2, ≥10.1 cm = 3.

AFP \<200 ng/mL = 1, 200-1000 ng/mL = 2, \>1000 ng/mL = 3.

Tumor number: 1 tumor = 1, 2-3 tumors = 2, ≥4 tumors = 3.

Adverse Events {#section13-1534735417734913}
--------------

After TACE treatment, postembolization syndrome, consisting of fever, abdominal pain, nausea, and a mild-to-moderate degree of ileus, is the most frequent complication, which is followed by infection. Infection should be considered when a patient presents with high fever (≥39.0 °C), or elevated WBC counts with increased neutrophil percentage, or positive blood culture for bacteria. Severe TACE-related complications may include oncolytic syndrome, tumor rupture, gastrointestinal bleeding, deep venous thrombosis, acute cholecystitis, femoral artery pseudoaneurysm, acute pancreatitis, acute hepatic failure, all of which contribute to TACE-related mortality (defined as the mortality occurring within 1 month post-TACE treatment). In our study, 14 patients in the TACE + KA group and 21 in the TACE group developed postembolization syndrome (29.2% vs 51.2%, *P* = .034). Ten patients in the TACE + KA group and 14 in the TACE group had infection (20.8% vs 34.1%, *P* = .158). No TACE-related mortality was recorded in both groups. As for KA treatment, 5 patients had mild allergic reaction (red, itchy and small rashes over the arms and body) after receiving KA infusion, which disappeared after stoppage of KA and receiving antihistamine therapy.

Discussion {#section14-1534735417734913}
==========

Currently, the therapeutic approaches to intermediate stage HCC are still disputed. There is substantial evidence supporting that hepatic resection is both safe and effective for treating selected patients with intermediate stage HCC (eg, a single tumor larger than 5cm in diameter or multiple tumors regardless of size and number),^[@bibr18-1534735417734913]^ and hepatic resection was shown to achieve a survival benefit over TACE.^[@bibr19-1534735417734913],[@bibr20-1534735417734913]^ Therefore, Galle et al^[@bibr21-1534735417734913]^ argued that the usage of the standard therapeutic approach (ie, TACE) for all intermediate stage HCC patients was probably an oversimplification and might not be appropriate for all patients, because intermediate stage HCC comprised the largest subgroup of patients with substantial disease heterogeneity, in which liver function impairment, tumor burden, serum α-fetoprotein level, microvascular invasion, and tumor differentiation contributed to the prognosis. Nevertheless, TACE was still recommended as the first-line therapy for intermediate stage HCC by the BCLC system due to the fact that HR is associated with substantial risks of liver failure and unacceptably high recurrence rates.^[@bibr18-1534735417734913]^

Since 2002, TACE was established as the standard of care for intermediate stage HCC when 2 randomized studies showed a survival benefit.^[@bibr11-1534735417734913],[@bibr22-1534735417734913]^ However, the outcomes of HCC treated by TACE remained unsatisfactory. Previous studies reported that the 1-, 2-, and 3-year survival rates ranged 57% to 82%, 31% to 63%, and 26% to 47%, respectively,^[@bibr11-1534735417734913],[@bibr22-1534735417734913]^ the median survival periods between 17.4 and 34 months,^[@bibr9-1534735417734913],[@bibr10-1534735417734913],[@bibr23-1534735417734913]^ and the median TTP periods from 4.9 to 7.9 months.^[@bibr23-1534735417734913][@bibr24-1534735417734913]-[@bibr25-1534735417734913]^ In the present study, we clearly demonstrated that adding adjuvant therapy of KA injection to TACE improved the efficacy of TACE per se in the treatment of intermediate stage HCC in BCLC classification system. Patients receiving both TACE and KA injections had significantly prolonged OS and TTP, higher survival rates, and reduced incidence of postembolization syndrome as well as lower frequencies of intrahepatic and extrahepatic metastases, when compared with those receiving only TACE.

As we know, TACE procedure can led to ischemic or hypoxic change of HCC, which elicits angiogenic activity, resulting in recurrence, proliferation, and metastasis of residual tumors.^[@bibr26-1534735417734913],[@bibr27-1534735417734913]^ In theory, a therapy that can compensate for the angiogenic and proliferative effects of TACE may improve the efficacy of TACE. As mentioned before, KA injection is a composite antitumor formula for injection that consists mainly of ginsenosides Rg1, Re, Rf, Rb1, and astragaloside.^[@bibr13-1534735417734913]^ Ginsenosides were shown to have anticancer, antioxidant, antiproliferative and anti-inflammatory properties. Li et al^[@bibr28-1534735417734913]^ reported that ginsenoside Rg1 is an effective anticancer and antioxidant constituent of total saponins of Panax ginseng, which has antitumor activity in TF-1/Epo cells by inhibiting TF-1/Epo cell proliferation and inducing cell apoptosis. Su et al^[@bibr29-1534735417734913]^ showed that ginsenoside Rg1 could inhibit mRNA expression and production of pro-inflammatory mediators, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS) from lipopolysaccharide (LPS)-stimulated macrophages. After heating, ginsenoside Re can convert into ginsenosides Rg2, Rg6, and F4, which have strong anticancer effects by causing S phase arrest, activating caspase-8, caspase-9, and caspase-3, and altering apoptotic factors such as Bcl-2 and Bax.^[@bibr30-1534735417734913]^ Ginsenoside Re can also inhibit mRNA expression and production of pro-inflammatory mediators (TNF-α, IL-1β, IL-6, COX-2, and iNOS).^[@bibr29-1534735417734913]^ Ginsenoside Rf can induce G2/M phase cell cycle arrest, cell apoptosis, upregulation of Bax and downregulation of Bcl-2, Cdk1, and cyclin B1, activation of caspase-3 and -9, and the release of cytochrome c in human osteosarcoma cell lines MG-63, OS732, U-2OS, HOS, and SAOS-2.^[@bibr31-1534735417734913]^ Nevertheless, Okita et al^[@bibr32-1534735417734913]^ argued that ginsenoside Rb1 had no anti-proliferative effects on human hepatoma cells.

Moreover, astragalosides were shown to possess antimetastatic and antiangiogenic effects. Astragaloside II can sensitize human cancerous cells resistant to 5-FU-induced cell death by inhibiting autophagy through MAPK-mTOR pathway to interfere with Beclin-1 and LC3.^[@bibr33-1534735417734913]^ Astragaloside IV when combined with curcumin displays synergistic effects in suppressing tumor growth and angiogenesis in an orthotopic nude-mouse model of human HCC.^[@bibr34-1534735417734913]^ Astragaloside IV can also attenuate the invasive and migratory abilities of HCC cells through the inhibition of epithelial-mesenchymal transition by targeting the Akt/GSK-3β/β-catenin pathway.^[@bibr35-1534735417734913]^

Our study showed that KA injection in combination with TACE was able to reduce the incidence of intrahepatic and extrahepatic metastases of HCC and postembolization syndrome compared with TACE alone, resulting in delayed TTP and improved survival benefits, which may be attributed to the anticancer, antiproliferative, antiangiogenic, antimetastatistic, and anti-inflammatory effects of the constituents in KA injection. These constituent molecules may work in a synergistic manner, which still needs to be clarified in future studies.

Our study had some discrepancies with previous studies in terms of median OS periods, survival rates and median TTP periods, which may be due to difference in patient selection, in terms of liver function status, etiology, maximum tumor size, number of tumor lesions, and other factors. Takayasu et al^[@bibr36-1534735417734913]^ showed that patients with Child-Pugh class A had better 3-year survival than patients with Child-Pugh class B after TACE treatment. Cantarini et al^[@bibr37-1534735417734913]^ demonstrated that patients with HBV-related HCC might have a worse prognosis than those with HCV-related HCC. Takayasu^[@bibr38-1534735417734913]^ reported that the 3-year survival of patients with 2 or 3 tumors \>3 cm or 4 or more tumors was 55% and 46% in Child-Pugh class A, respectively, and 30% and 22% in class B, respectively. In our study, male patients accounted for more than 75%, Child-Pugh class B more than 50%, HBV infection more than 65%, large tumor larger than 5 cm more than 60%, and multiple lesions more than 55%. Differences in these factors may account for the discrepant clinical outcomes between our study and others. Zhu et al^[@bibr39-1534735417734913]^ reported that AFP ≥400 ng/mL, vascular invasion and TACE treatment were associated with patient survival after TACE. Takayasu et al^[@bibr9-1534735417734913]^ reported that degree of liver damage, maximum tumor size, number of lesions, and portal vein invasion were independent predictors for patient survival after TACE. In our study, we found that group (or treatment modality), maximum tumor size, and tumor number were significant predictors for OS, while group (or treatment modality), maximum tumor size and AFP level were independent predictors for TTP, which is similar to these studies.

Our study had the following limitations. First, the sample sizes in the TACE + KA and TACE groups were limited. Second, the treatment allocation was not randomized. Third, the follow-up period was relatively short, for only 40 months.

Conclusions {#section15-1534735417734913}
===========

In summary, our study showed that adding adjuvant therapy of KA injection to TACE improved the efficacy of TACE alone in the treatment of intermediate HCC with delayed tumor progression, improved patient survival, and reduced postembolization syndrome, which is probably associated with the anti-inflammatory, antitumor, and antimetastatic effects of KA constituents. More randomized, controlled trials with larger sample sizes and those recruiting patients with more diverse backgrounds are warranted to achieve more reliable results.
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